164 related articles for article (PubMed ID: 17009919)
1. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation.
Asanuma M; Miyazaki I
Expert Rev Neurother; 2006 Sep; 6(9):1313-25. PubMed ID: 17009919
[TBL] [Abstract][Full Text] [Related]
2. [New aspects of neuroprotective effects of nonsteroidal anti-inflammatory drugs].
Asanuma M; Miyazaki I; Tsuji T; Ogawa N
Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Jun; 23(3):111-9. PubMed ID: 12884751
[TBL] [Abstract][Full Text] [Related]
3. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease.
Asanuma M; Miyazaki I
Curr Pharm Des; 2008; 14(14):1428-34. PubMed ID: 18537665
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases.
Asanuma M; Miyazaki I; Ogawa N
Curr Pharm Des; 2004; 10(6):695-700. PubMed ID: 14965332
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
6. PPAR: a therapeutic target in Parkinson's disease.
Chaturvedi RK; Beal MF
J Neurochem; 2008 Jul; 106(2):506-18. PubMed ID: 18384649
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald A; Lotharius J
Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
[TBL] [Abstract][Full Text] [Related]
8. [Mechanism of specific dopaminergic neuronal death in Parkinson's disease].
Ogawa N; Asanuma M; Miyoshi K
Nihon Rinsho; 2004 Sep; 62(9):1629-34. PubMed ID: 15462376
[TBL] [Abstract][Full Text] [Related]
9. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
Tsai SJ
Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying drugs and Parkinson's disease.
Allain H; Bentué-Ferrer D; Akwa Y
Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
12. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
Fiorucci S; Santucci L; Distrutti E
Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
[TBL] [Abstract][Full Text] [Related]
13. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.
Fumagalli F; Racagni G; Riva MA
Pharmacogenomics J; 2006; 6(2):95-104. PubMed ID: 16402079
[TBL] [Abstract][Full Text] [Related]
14. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
Verma R; Nehru B
Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
[TBL] [Abstract][Full Text] [Related]
15. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Miyoshi K; Ogawa N; Murata M
Neurosci Res; 2008 Jan; 60(1):106-13. PubMed ID: 18022268
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action.
Park HJ; Lee PH; Ahn YW; Choi YJ; Lee G; Lee DY; Chung ES; Jin BK
Eur J Neurosci; 2007 Jul; 26(1):79-89. PubMed ID: 17581257
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.
Joyce JN; Millan MJ
Curr Opin Pharmacol; 2007 Feb; 7(1):100-5. PubMed ID: 17174156
[TBL] [Abstract][Full Text] [Related]
18. Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Ogawa N
Acta Med Okayama; 2004 Oct; 58(5):221-33. PubMed ID: 15666991
[TBL] [Abstract][Full Text] [Related]
19. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
20. A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition.
Zafar KS; Siegel D; Ross D
Mol Pharmacol; 2006 Sep; 70(3):1079-86. PubMed ID: 16790533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
